BRD9 and acute myeloid leukemia: BRD9 is unique to the ncBAF complex and its genetic and pharmacological inhibition is reported to induce synthetic lethality in several cancers, including acute myeloid leukemia (AML) [23–26], synovial sarcoma, non-small cell lung cancer and prostate cancer [27–29].